- Email: [email protected]
Hepatitis C virus DNA sequence and protein sequence; recombinant vaccine and DNA probe for disease diagnosis
Patent Report virus genes; vi. a method for the preparation of non-A non-B hepatitis virus antigenic protein by expression from recombinant vaccinia virus; vii. their expression products having sugars; and viii. vaccines comprising the sugar-containing expressed non-A non-B hepatitis virus antigen proteins or attenuated or inactivated recombinant vaccinia viruses. In an example, recombinant vaccinia virus was grown in rabbit kidney RK-13 cell cultures. 093-93
Hepatitis C virus DNA sequence and protein sequence; recombinant vaccine and DNA probe for disease diagnosis Kaoaku-Oyobi-Kessei-Ryoho-Kenkyusho Jpn 5068 563; 23 March 1993
The following are claimed: (1) all or part of a specified DNA sequence encoding a hepatitis C virus (HCV) protein; (2) all or part of a protein sequence corresponding to the protein of (1); (3) preparation of (2) by expression of a vector containing a nucleotide fragment of (1) in host cells; (4) detection of HCV by hybridization of nucleotides in a sample with the probes of the nucleotide fragment (over 10 bases) of (1); (5) detection of HCV using the HCV proteins of (2) and (3) as antigens; (6) detection of HCV antibody of (5) by ELISA, radioimmunoassay, Western blotting or an agglutination method; (7) production of HCV antibody using the HCV proteins of (2) and (3) as antigens; (8) the immunological detection of HCV and its related antigens using the antibodies of (7); (9) production of a HCV vaccine using the HCV proteins of (2) and (3) as antigens; and (10) production of HCV particles by the introduction and infection of nucleic acids of (1) into a mammal cell culture. In an example, the plasma from a patient was concentrated 1000 times. RNA was extracted from the plasma and eDNA was synthesized and cloned into a phage lambda-gtl 1 vector. 094-93
Type-C-like human retrovirus associated with multiple sclerosis, and monoclonal antibody and anti-idiotype antibody; and attenuated Epstein-Barr virus vaccine; DNA probe and RNA probe for application in diagnosis and therapy Danish M S Soc. World 9307 259; 15 April 1993
The following are new: (1) a cell culture comprising cells which are affected with a type-C-like retrovirus associated with
1268 Vaccine, Vol. 11, Issue 12, 1993
multiple sclerosis which shows negative results when tested by polymerase chain reaction (PCR) and immunofluorescence analysis; (2) a cell culture comprising cells as in (1), but which also shows positive results in Western blotting, reversetranscriptase (EC 2.7.7.49) and PCR; (3) a purified retrovirus (RV) as in (1); (4) a purified RV as in (2); (5) antigens or epitopes derived from, produced by or induced by (3) or (4); (6) a monoclonal antibody binding to the epitope of (5) and a method to produce it; (7) an anti-idiotype antibody (Ab) directed against the site of the Ab of (6); (8) a nucleic acid (NA) sequence, distinct from known RVs, obtained by isolating NAs from (1) or (2) or the purified RV of (1) or (2); (9) a NA sequence obtained using a RV-related nucleotide primer recognizing conserved regions of known RVs to obtain nucleotide sequences derived from (1) or (2); and (10) a vaccine comprising attenuated Epstein-Barr virus; and (11) methods for diagnosis of MS. 095-93
Vaccine comprising part of constant region of IgE; antiallergic recombinant vaccine production by IgE epsilon chain constant CH2-CH3 domain fusion protein expression in Escherichia coN; may be used in asthma, allergy and eczema therapy Hellman L. World 9305 810; 1 April 1993
A vaccine for alleviating the symptoms of or preventing the induction of IgE-mediated allergic reactions in a mammal is claimed, comprising a protein having the entire amino acid sequence of the constant CH2-CH3 domains of the epsilon chain of the IgE molecule from the desired mammal sp., or a structurally stable unit of the amino acid sequence containing more than 12 amino acids, in its original form or in a mutated or multimerized form. The vaccine may optionally contain an adjuvant. The vaccine is coupled to one or more heterologous carrier proteins. The vaccine protein is preferably prepared by cloning the cDNA sequence for the amino acid sequence of the entire CH2-CH3 domain of the IgE epsilon chain or structurally stable unit and expressing it as a fusion protein in a eukaryotic or prokaryotic host, preferably Escherichia coli. By using only the CH2-CH3 region of the IgE molecule, the body after immunization forms antibodies against the region of the IgE interacting with the IgE receptor. The method can be used in the treatment of e.g. asthma, allergies and eczema. 096-93
Hepatitis C virus DNA sequence and protein sequence; recombinant vaccine and DNA probe for disease diagnosis Kaoaku-Oyobi-Kessei-Ryoho-Kenkyusho Jpn 5068 563; 23 March 1993
The following are claimed: (1) all or part of a specified DNA sequence encoding a hepatitis C virus (HCV) protein; (2) all or part of a protein sequence corresponding to the protein of (1); (3) preparation of (2) by expression of a vector containing a nucleotide fragment of (1) in host cells; (4) detection of HCV by hybridization of nucleotides in a sample with the probes of the nucleotide fragment (over 10 bases) of (1); (5) detection of HCV using the HCV proteins of (2) and (3) as antigens; (6) detection of HCV antibody of (5) by ELISA, radioimmunoassay, Western blotting or an agglutination method; (7) production of HCV antibody using the HCV proteins of (2) and (3) as antigens; (8) the immunological detection of HCV and its related antigens using the antibodies of (7); (9) production of a HCV vaccine using the HCV proteins of (2) and (3) as antigens; and (10) production of HCV particles by the introduction and infection of nucleic acids of (1) into a mammal cell culture. In an example, the plasma from a patient was concentrated 1000 times. RNA was extracted from the plasma and eDNA was synthesized and cloned into a phage lambda-gtl 1 vector. 094-93
Type-C-like human retrovirus associated with multiple sclerosis, and monoclonal antibody and anti-idiotype antibody; and attenuated Epstein-Barr virus vaccine; DNA probe and RNA probe for application in diagnosis and therapy Danish M S Soc. World 9307 259; 15 April 1993
The following are new: (1) a cell culture comprising cells which are affected with a type-C-like retrovirus associated with
1268 Vaccine, Vol. 11, Issue 12, 1993
multiple sclerosis which shows negative results when tested by polymerase chain reaction (PCR) and immunofluorescence analysis; (2) a cell culture comprising cells as in (1), but which also shows positive results in Western blotting, reversetranscriptase (EC 2.7.7.49) and PCR; (3) a purified retrovirus (RV) as in (1); (4) a purified RV as in (2); (5) antigens or epitopes derived from, produced by or induced by (3) or (4); (6) a monoclonal antibody binding to the epitope of (5) and a method to produce it; (7) an anti-idiotype antibody (Ab) directed against the site of the Ab of (6); (8) a nucleic acid (NA) sequence, distinct from known RVs, obtained by isolating NAs from (1) or (2) or the purified RV of (1) or (2); (9) a NA sequence obtained using a RV-related nucleotide primer recognizing conserved regions of known RVs to obtain nucleotide sequences derived from (1) or (2); and (10) a vaccine comprising attenuated Epstein-Barr virus; and (11) methods for diagnosis of MS. 095-93
Vaccine comprising part of constant region of IgE; antiallergic recombinant vaccine production by IgE epsilon chain constant CH2-CH3 domain fusion protein expression in Escherichia coN; may be used in asthma, allergy and eczema therapy Hellman L. World 9305 810; 1 April 1993
A vaccine for alleviating the symptoms of or preventing the induction of IgE-mediated allergic reactions in a mammal is claimed, comprising a protein having the entire amino acid sequence of the constant CH2-CH3 domains of the epsilon chain of the IgE molecule from the desired mammal sp., or a structurally stable unit of the amino acid sequence containing more than 12 amino acids, in its original form or in a mutated or multimerized form. The vaccine may optionally contain an adjuvant. The vaccine is coupled to one or more heterologous carrier proteins. The vaccine protein is preferably prepared by cloning the cDNA sequence for the amino acid sequence of the entire CH2-CH3 domain of the IgE epsilon chain or structurally stable unit and expressing it as a fusion protein in a eukaryotic or prokaryotic host, preferably Escherichia coli. By using only the CH2-CH3 region of the IgE molecule, the body after immunization forms antibodies against the region of the IgE interacting with the IgE receptor. The method can be used in the treatment of e.g. asthma, allergies and eczema. 096-93